Sino Biopharmaceutical Limited Stock Current Valuation
| SBMFF Stock | USD 0.42 0.00 0.00% |
Valuation analysis of Sino Biopharmaceutical helps investors to measure Sino Biopharmaceutica's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Sino Biopharmaceutica's price fluctuation is abnormally volatile at this time. Calculation of the real value of Sino Biopharmaceutical is based on 3 months time horizon. Increasing Sino Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Sino pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Sino Biopharmaceutical Limited. Since Sino Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sino Pink Sheet. However, Sino Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.42 | Real 0.35 | Hype 0.42 | Naive 0.41 |
The real value of Sino Pink Sheet, also known as its intrinsic value, is the underlying worth of Sino Biopharmaceutical Company, which is reflected in its stock price. It is based on Sino Biopharmaceutica's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sino Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sino Biopharmaceutical Limited helps investors to forecast how Sino pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sino Biopharmaceutica more accurately as focusing exclusively on Sino Biopharmaceutica's fundamentals will not take into account other important factors: Sino Biopharmaceutical Limited Company Current Valuation Analysis
Sino Biopharmaceutica's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sino Biopharmaceutica Current Valuation | 10.34 B |
Most of Sino Biopharmaceutica's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sino Biopharmaceutical Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sino Biopharmaceutical Limited has a Current Valuation of 10.34 B. This is 28.01% lower than that of the Healthcare sector and 122.58% higher than that of the Biotechnology industry. The current valuation for all United States stocks is 37.8% higher than that of the company.
Sino Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sino Biopharmaceutica's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sino Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Sino Biopharmaceutica by comparing valuation metrics of similar companies.Sino Biopharmaceutica is currently under evaluation in current valuation category among its peers.
Sino Fundamentals
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 | |||
| Profit Margin | 0.29 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 10.34 B | |||
| Shares Outstanding | 18.81 B | |||
| Shares Owned By Insiders | 47.86 % | |||
| Shares Owned By Institutions | 14.86 % | |||
| Price To Earning | 24.17 X | |||
| Price To Book | 2.51 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 26.86 B | |||
| Gross Profit | 21.53 B | |||
| EBITDA | 19.87 B | |||
| Net Income | 14.61 B | |||
| Cash And Equivalents | 15.67 B | |||
| Cash Per Share | 0.85 X | |||
| Total Debt | 5.21 B | |||
| Debt To Equity | 0.31 % | |||
| Current Ratio | 1.55 X | |||
| Book Value Per Share | 1.64 X | |||
| Cash Flow From Operations | 5.37 B | |||
| Earnings Per Share | 0.06 X | |||
| Price To Earnings To Growth | 0.53 X | |||
| Number Of Employees | 25.55 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 10.91 B | |||
| Total Asset | 60.54 B | |||
| Working Capital | 6 B | |||
| Current Asset | 13.73 B | |||
| Current Liabilities | 7.73 B | |||
| Z Score | 1.2 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 0.74 % | |||
| Net Asset | 60.54 B | |||
| Last Dividend Paid | 0.083 |
About Sino Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sino Biopharmaceutical Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sino Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sino Biopharmaceutical Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sino Pink Sheet
Sino Biopharmaceutica financial ratios help investors to determine whether Sino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sino with respect to the benefits of owning Sino Biopharmaceutica security.